Mycotoxins

News

DSM completes acquisition of Biomin and Romer Labs

Royal DSM announced the completion of its acquisition of Biomin and Romer Labs, both part of the Erber Group, for an enterprise value of € 980 million.

The acquisition of Erber Group was first announced on 12 June 2020. DSM states in a press release that the transaction is expected to be earnings enhancing in the 1st year upon completion.

Photo: Hugo Claver
Photo: Hugo Claver

Erber Group’s Biomin specialises primarily in mycotoxin risk management and gut health performance management, whereas the Romer Labs business focuses on food and feed safety diagnostic solutions. According to DSM the acquisition of Erber Group’s Biomin further strengthens DSM’s expertise and is much aligned with DSM’s focus to make animal farming more sustainable from both an ecological and economical perspective.

Romer Labs also complements DSM’s human nutrition and health offering to customers in the food & beverages market segments.

DSM

DSM delivers solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about € 10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam.